Inspire Advisors LLC Acquires 236 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Inspire Advisors LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.1% in the fourth quarter, Holdings Channel reports. The fund owned 2,584 shares of the medical research company’s stock after purchasing an additional 236 shares during the quarter. Inspire Advisors LLC’s holdings in IQVIA were worth $508,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Private Trust Co. NA lifted its holdings in shares of IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after acquiring an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its holdings in shares of IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after acquiring an additional 50 shares during the last quarter. Howard Capital Management Inc. raised its position in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the period. Huntington National Bank raised its position in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after purchasing an additional 56 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after purchasing an additional 56 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Robert W. Baird reduced their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Truist Financial reissued a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Leerink Partners reissued an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Finally, Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Performance

Shares of IQV stock opened at $183.72 on Wednesday. The firm has a market cap of $32.39 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.50. The company’s 50 day moving average is $197.36 and its 200 day moving average is $211.78. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.72.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.